Certara

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Certara surpasses revenue expectations, eyes global expansion and innovation

Certara's strong financial performance in Q4 2022 and exceeding revenue guidance for the full year underscore the company's growth trajectory and market positioning.
With a focus on software, biosimulation services, and global expansion, Certara is poised for continued success in 2023 and beyond.
The company's proactive engagement with regulatory bodies, strategic acquisitions, and partnerships signal a commitment to innovation and sustainable growth.

Certara reports robust Q1 earnings driven by biosimulation strength

Certara's Q1 2023 showcased solid financial performance, particularly in software and biosimulation services. Despite challenges in deal closure times and subscription model impact, the company remains optimistic about future growth opportunities.

Certara reports solid Q2 earnings, eyes growth through AI integration

Certara's Q2 performance showed growth in both software and services revenue, with adjusted EBITDA at $32.4 million.
The company faces challenges from cautious spending and slow recovery in regulatory business but remains optimistic about long-term industry potential.
Strengths include acquisitions enhancing AI capabilities, focus on accelerating projects, and expanding key offerings.
Opportunities lie in integrating AI, driving growth in biosimulation services, and aiming for higher growth in 2024.

Certara reports stable Q3 performance, eyes growth in biosimulation and AI

Certara's Q3 performance showed revenue growth driven by software, despite challenges in services revenue.
The company remains confident in its strategies and outlook for growth, focusing on biosimulation and AI integration.
While facing uncertainties in closing AI product deals, Certara sees opportunities in market demand and long-term growth.
Analysts' inquiries during the call highlighted areas of concern but also underscored Certara's strengths and potential for expansion.

Certara reports steady revenue growth, eyes software investments for 2024

Certara's Q4 2023 performance reflects a mixed revenue picture with software revenue growth offsetting a decline in services revenue, while the company maintains a strong financial position.
Strategic acquisitions, growth initiatives in key markets, and a focus on operational efficiency present avenues for Certara to drive future growth and enhance market competitiveness.
Challenges lie in balancing revenue streams, managing margin pressures from investments, and navigating market uncertainties, requiring strategic decision-making and operational agility.
Overall, Certara's outlook for 2024 is optimistic, underpinned by confidence in growth drivers, strategic acquisitions, and a commitment to innovation and market expansion.

Certara reports solid Q1 performance and eyes revenue acceleration

Certara's Q1 performance reflects growth in software revenue and steady services revenue, with a focus on operational efficiency and strategic goals for 2024.
Challenges include seasonality in services bookings and the need for further restructuring, while opportunities lie in potential revenue acceleration and market dynamics.
Overall, Certara remains optimistic for the year ahead, maintaining revenue and EPS guidance for 2024 and aiming for margin improvement in the second half.

Certara reports Q2 revenue growth, acquires Chemaxon for innovation

Certara's Q2 performance showed mixed results with revenue growth driven by Software but offset by a decline in Services, while bookings and adjusted EBITDA demonstrated positive momentum.
The company's strategic strengths lie in recent acquisitions, product innovations, and a focus on software and AI investments to drive future growth and profitability.
Challenges include addressing declines in the Services segment, improving performance with Tier 1 customers, and managing operational costs to reduce net losses.
Opportunities for Certara include meeting full-year revenue guidance, leveraging software and AI investments for industry leadership, and expanding market presence through recent acquisitions and product releases.

Certara reports strong Q3 earnings, focuses on biosimulation growth

Certara's Q3 performance was strong, driven by revenue growth and strategic investments in software and commercial reach.
While facing challenges in the regulatory services market, Certara is focused on leveraging opportunities from the Chemaxon acquisition and uniting R&D and sales efforts for sustainable growth.
The company's financial position is robust with healthy cash reserves, but managing debt levels and maintaining margins in regulatory services remain key challenges.
Certara's outlook for 2024 is positive, with updated guidance indicating revenue of $380-385 million and adjusted EBITDA of $120-124 million.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Radnor, PA.

Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript

Certara, Inc. (CERT) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.11 per share a year ago.

Certara, Inc. (CERT) Q3 Earnings Surpass Estimates

RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024.

Certara Reports Third Quarter 2024 Financial Results

RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference.

Certara to Participate in the Stephens Annual Investment Conference

RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024.

Certara Appoints John Reynders as New Independent Board Member

RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.

Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024

Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.

Certara Completes Acquisition of Chemaxon

Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001.

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug

RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5.

Certara Launches Phoenix™ Version 8.5 Drug Development Software

Certara, Inc. (NASDAQ:CERT ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens David Windley - Jefferies Dan Clark - Leerink Partners Joe Vruwink - Baird Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara Second Quarter 2024 Earnings Conference Call.

Certara, Inc. (CERT) Q2 2024 Earnings Call Transcript

Certara, Inc. (CERT) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.12 per share a year ago.

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2024.

Certara Reports Second Quarter 2024 Financial Results

Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024 guidance RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software.

Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio

RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.

Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024

Certara today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers.

Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software

RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference.

Certara to Participate in the Jefferies Global Healthcare Conference

RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel.

Certara Appoints New Chief Human Resources Officer & General Counsel

Certara, Inc. (NASDAQ:CERT ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants David Windley - Jefferies Luke Sergott - Barclays Michael Ryskin - Bank of America Max Smock - William Blair Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara First Quarter 2024 Earnings Conference Call.

Certara, Inc. (CERT) Q1 2024 Earnings Call Transcript

Certara, Inc. (CERT) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.12 per share a year ago.

Certara, Inc. (CERT) Q1 Earnings Meet Estimates

PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024.

Certara Reports First Quarter 2024 Financial Results

Certara Cloud is a unifying platform that integrates Certara's scientific software. Clients use a single ID to access and manage their licensed software.

Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform

PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.

Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference

Certara Inc. (CERT) Q4 2023 Earnings Call Transcript

Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.16 per share a year ago.

News for Certara Stock (CERT)